PDGFRB and neoplasm: Abnormal activation of receptor tyrosine kinases (RTKs), such as EGFR, VEGFR2/3, and PDGFR-β, is also involved in the dysregulation of MEK-ERK signaling, leading to tumor progression [52,53,54,55,56].